Inhibrx Biosciences earnings were -$163.7M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest INBX earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$28.7M, down 33.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, INBX reported annual earnings of $1.7B, with -799.2% growth. The next INBX earnings date is Nov 13, 2025.
Inhibrx Biosciences Earnings Reports & History FAQ
What were Inhibrx Biosciences's earnings last quarter?
Inhibrx Biosciences (NASDAQ: INBX) reported Q2 2025 earnings per share (EPS) of -$1.85, up 101.46% year over year. Total INBX earnings for the quarter were -$28.65 million. In the same quarter last year, Inhibrx Biosciences's earnings per share (EPS) was $127.10.
The next INBX earnings date is Invalid Date. Add INBX to your watchlist to be reminded of Inhibrx Biosciences's next earnings date.
Is Inhibrx Biosciences profitable or losing money?
As of the last Inhibrx Biosciences earnings report, Inhibrx Biosciences is currently losing money. Inhibrx Biosciences's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$163.69 million, a 110.02% decrease year over year.
What was INBX's earnings growth in the past year?
As of Inhibrx Biosciences's earnings date in Q4 2025, Inhibrx Biosciences's earnings has grown year over year. INBX earnings in the past year totalled -$163.69 million.
What are Inhibrx Biosciences's earnings expectations?
The current EPS estimate for Inhibrx Biosciences's earnings report in Invalid Date is -$1.57.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.